Market Challenges And Opportunities

Human Papillomavirus (HPV) Infection Vaccines Market Driver

Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. According to World Health Organization (WHO), 2014, HPV type 6 and type 11 are responsible for 90% of the anogenital warts.

Human Papillomavirus (HPV) Infection Vaccines Market Restrains

The human papillomavirus infection vaccine market is expected to constrain by limited number of Food and Drug Administrations (FDA) approved commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. Moreover, variable immunization coverage is estimated to impact the regional size. For instance, economies such as U.K and Mexico has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.